Ovarian cancer: Early relapse
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Ovarian cancer: Early relapse |
| Type de publication | Journal Article |
| Year of Publication | 2017 |
| Auteurs | Pautier P, Kalbacher E, Rouge TDe la Mott, Bonnetain F, Lesoin A |
| Journal | BULLETIN DU CANCER |
| Volume | 104 |
| Pagination | S32-S38 |
| Date Published | MAY |
| Type of Article | Article |
| ISSN | 0007-4551 |
| Mots-clés | Early relapse, Ovarian cancer |
| Résumé | Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A). |
| DOI | 10.1016/S0007-4551(17)30160-1 |